A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics
Molecular Pharmaceutics · 05.02.2024 · 21 (2) · 491-500
DOI: 10.1021/acs.molpharmaceut.3c00561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 12.01.2024. Verfasst von Marwa Elkhashab und 4 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark. Hauptthemen laut MEDLINE: Oligonucleotides, Osteoarthritis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: H2020 Marie Sklodowska-Curie Actions, Dutch Arthritis Society, Turkish Government.
Abstract (Originalsprache)
Antisense nucleic acid drugs are susceptible to nuclease degradation, rapid renal clearance, and short circulatory half-life. In this work, we introduce a modular-based recombinant human albumin-oligonucleotide (rHA-cODN) biomolecular assembly that allows incorporation of a chemically stabilized therapeutic gapmer antisense oligonucleotide (ASO) and FcRn-driven endothelial cellular recycling. A phosphodiester ODN linker (cODN) was conjugated to recombinant human albumin (rHA) using maleimide chemistry, after which a complementary gapmer ASO, targeting ADAMTS5 involved in osteoarthritis pathogenesis, was annealed. The rHA-cODN/ASO biomolecular assembly production, fluorescence labeling, and purity were confirmed using polyacrylamide gel electrophoresis. ASO release was triggered by DNase-mediated degradation of the linker strand, reaching 40% in serum after 72 h, with complete release observed following 30 min of incubation with DNase. Cellular internalization and trafficking of the biomolecular assembly using confocal microscopy in C28/I2 cells showed higher uptake and endosomal localization by increasing incubation time from 4 to 24 h. FcRn-mediated cellular recycling of the assembly was demonstrated in FcRn-expressing human microvascular endothelial cells. ADAMTS5 in vitro silencing efficiency reached 40%, which was comparable to free gapmer after 72 h incubation with human osteoarthritis patients' chondrocytes. This work introduces a versatile biomolecular modular-based "Plug-and-Play" platform potentially applicable for albumin-mediated half-life extension for a range of different types of ODN therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus C, Denmark.
- Department of Orthopedics, University Medical Center Utrecht, 3584 CT Utrecht, The Netherlands.
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark.
ORCID-Profile: Marwa Elkhashab, Laura B Creemers, Kenneth A Howard
Förderung
- H2020 Marie Sklodowska-Curie Actions
- Dutch Arthritis Society
- Turkish Government
Zitieren
APA
Elkhashab, M., Dilek, Y., Foss, M., Creemers, L. B., & Howard, K. A. (2024). A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics. Molecular Pharmaceutics, 21(2), 491-500. https://doi.org/10.1021/acs.molpharmaceut.3c00561
Vancouver
Elkhashab M, Dilek Y, Foss M, Creemers LB, Howard KA. A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics. Molecular Pharmaceutics. 2024;21(2):491-500. doi:10.1021/acs.molpharmaceut.3c00561
BibTeX
@article{Elkhashab2024,
author = {Elkhashab, Marwa and Dilek, Yeter and Foss, Morten and Creemers, Laura B and Howard, Kenneth A},
title = {A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {2},
pages = {491--500},
doi = {10.1021/acs.molpharmaceut.3c00561}
}
EUVIMED